Navigation Links
MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP?
Date:11/20/2007

WHO: Eularis

WHAT: Presentation on Marketing Return: What can be measured?

WHEN: 26 November 2007 at 2:30 p.m. GMT WHERE: Pharmaceutical Marketing Society Half-day Conference, 20 Cavendish

Square, London

NEW YORK and LONDON, Nov. 20 /PRNewswire/ -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on marketing return at the Pharmaceutical Marketing Society Half-day Conference: ROI or RIP.

*(LOGO 72dpi: Send2Press.com/mediaboom/07-0924-Eularis_72dpi.jpg)

At 2:30 p.m. on Monday 26 November 2007, Dr. Bates will deliver a presentation titled, "What Can Be Measured?" Bates will challenge the thinking of conference attendees and will expose where ROI goes wrong, the limitations of ROI and what can and should be measured. She will also provide attendees with ideas on how to put ROI to work in their own pharmaceutical organizations.

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates' leadership, Eularis issued two related research reports this year, including Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? (http://www.pharmaindustrysfe.com/) and Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line (http://www.pharmamarketingroi.com/).

The Pharmaceutical Marketing Society Half-day Conference takes place in London. The conference will be focused on answering two pivotal questions: "Are you maximising the return on investment from your marketing spend?" and "Do you know where your marketing spend is having the most effect?" For more information, visit: http://www.pmsociety.org.uk/events/roi.

To arrange an interview with Eularis, please contact Jennifer Humiston at +1 617.779.1812 or via email at jhumiston@shiftcomm.com.

About Eularis

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Eularis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AUDIO from Medialink and Radica: Staying Sharp with Games for Your Brain
2. AUDIO from Medialink and Kelloggs: Whats in Your Water?
3. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
4. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
5. Justice Department to Hold Media Event to Demonstrate New Database for Matching Unidentified Remains and Missing Persons Information
6. Weiner Public News First Media Team at National Press Club 5K
7. VIDEO from Medialink and General Motors: On and Off the Track
8. HealthMedia Revolution Explodes in Second Quarter
9. AUDIO from Medialink and Pfizer: Prescription for Safer Drugs Discussed in Washington
10. AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care
11. AUDIO from Medialink and Pfizer: A New Prescription for Safer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: